Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TANK drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TANK Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for PPI assays. |
View TANK Products |
| Gene Delivery | TANK Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and functional pathway validation. |
View TANK Products |
| Benchmark Ab | Anti-TANK Antibody Recombinant positive control for Western Blot, Immunoprecipitation, and ELISA. |
View TANK Products |
| Validator | TANK siRNA Set For specific knockdown verification in cellular assays. |
View TANK Products |
| Related Target A | TBK1 Critical downstream kinase activated by the TANK-TRAF complex in antiviral and inflammatory signaling. |
View TBK1 Products |
| Related Target B | TRAF2 Scaffold protein interacting directly with TANK to modulate NF-kappa-B activation. |
View TRAF2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular Protein-Protein Interaction (PPI) screening | High-purity recombinant proteins expressed with precise tag design (GST/His) for GST-pull down or AlphaLISA. |
| Cellular pathway modulation assay setup | Lentivirus premade particles for stable over-expression to monitor NF-kB activation in reporter cell lines. |
| Lack of Controls | Sequence-verified benchmark antibodies and functional siRNA pools included for assay validation. |
| False Positives in Screening | Endotoxin-controlled, highly purified proteins ensuring no non-specific immune activation. |
Live TANK R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TANK therapeutics is intensifying, with major players shifting focus from traditional systemic cytokine inhibition to targeted intracellular pathway modulation. As first-generation broad-spectrum anti-inflammatory therapies reach their clinical limits, the next wave of R&D is targeting the TANK-TRAF-TBK1 signalosome to achieve tissue-specific and pathway-specific immunomodulation without inducing systemic immunosuppression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI Inhibitors | Academic Institutes, Biotech Startups | Autoimmune Diseases, SLE | In vitro binding assays (Need high-purity GST-tagged TANK and TRAF proteins) |
| PROTAC / Degraders | Targeted Protein Degradation Companies | Inflammatory Diseases, Oncology | Degradation kinetics assays (Need stable TANK-expressing cell lines via Lentivirus) |
| siRNA Therapeutics | RNAi Therapeutics Developers | Glomerulonephritis, Viral Infections | Knockdown efficiency validation (Need validated siRNA and high-specificity antibodies) |